Anemia is one of the many serious consequences of chronic kidney disease (CKD) that often goes unrecognized and undertreated, leaving patients with low quality of life and at risk for increased morbidity and mortality.1,2 For many years, the standard treatment for anemia in CKD has been erythropoiesis-stimulating agents (ESAs) with iron; however, the full correction of hemoglobin (Hb) with ESAs has been called into question due to safety concerns.2,3 Fortunately, new insights into the pathophysiology of anemia have revealed novel treatment targets that may overcome the limitations associated with ESA use.4 Increased understanding of hepcidin and hypoxia-inducible factor (HIF) in anemia has led to the development of HIF-prolyl hydroxylase (HIF-PH) inhibitors. These oral small molecules have demonstrated Hb correction with lower peak serum erythropoietin levels and good overall tolerability. HIF-PH inhibitors are currently being investigated for the treatment of anemia in CKD, myelodysplastic syndromes (MDS), and other disease states.4-6 This ACPE-accredited symposium will provide expert insights into emerging therapies for anemia management in CKD. The faculty panel will explore the latest clinical trial data for HIF-PH inhibitors and discuss how these novel, oral agents compare to ESAs, biosimilars, and other therapies for anemia management.

1Stauffer ME, et al. PLoS One. 2014; 2Locatelli F, et al. Am J Nephrol. 2017; 3Kaplan JM, et al. Int J Mol Sci. 2018; 4Bernhardt WM, et al. J Am Soc Nephrol. 2006; 5Gupta N, et al. Am J Kidney Dis. 2017; 6Kular D, et al. Pediatr Nephrol. 2018.

View All Speakers


Calvin Meaney, PharmD, BCPS

View Full Bio

Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF

View Full Bio

Thomas Dowling, PharmD, PhD, FCCP

View Full Bio



In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This application-based activity is approved for 1.50 contact hours (0.150 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-18-016-L01-P).


Creative Educational Concepts, Inc. certifies this activity for 1.50 hours of participation.


Presented by Creative Educational Concepts, Inc. (CEC) and supported through an independent educational grant from AstraZeneca.